Eosinophilic esophagitis (EoE) is a chronic immune system disease of the esophagus. In EoE, a large number of white blood cells called eosinophils are found in the inner lining of the esophagus. This buildup, which is a reaction to food, allergen, or acid reflux, can inflame or injure the esophageal tissue. Difficulties in swallowing, impaction, chest pain often centrally located that does not respond to antacids, and the backflow of undigested food are the signs and symptoms of eosinophilic esophagitis in adults.
The global eosinophilic esophagitis market is estimated to be valued at US$ 138.4 million in 2021 and is expected to exhibit a CAGR of 33.3% during the forecast period (2021-2028).
Figure 1. Global Eosinophilic Esophagitis Market in Terms of Value (US$ million), By Region, 2021
Promising results for potential drug candidates are estimated to drive the global eosinophilic esophagitis market growth during the forecast period.
|Base Year:||2020||Market Size in 2021:||US$ 138.4 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||33.3%||2028 Value Projection:||US$ 1,037.2 Mn|
Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH
|Restraints & Challenges:||
Figure 2.Global Eosinophilic Esophagitis Market Share (%), By Drug Class, 2021
Increasing awareness programs for Eosinophil-associated disorders is anticipated to propel the global eosinophilic esophagitis market growth over the forecast period.
Various awareness programs have been developed and implemented to educate the public and medical community about eosinophil-associated disorders which is anticipated to drive the market growth over the forecast period. The American Partnership for Eosinophilic Disorders (APFED), a nonprofit organization, was founded in December 2001, which works on educating, raising awareness, supporting, and advocating for patients and families who are suffering from eosinophil-associated diseases.
Global Eosinophilic Esophagitis Market – Impact of Coronavirus (COVID-19) Pandemic
Global Eosinophilic Esophagitis Market: Restraints
As of now, no specific treatment has been approved for eosinophilic esophagitis in the U.S. Market players are focusing on developing drug candidates for the treatment of EoE. However, there are many challenges associated with obtaining approval from the regulatory authorities which is anticipated to hinder the market growth over the forecast period. Obtaining approval for the drug from regulatory authorities is a tedious and challenging as regulatory authorities such as the U.S. Food and Drug Administration (FDA) impose substantial and burdensome requirements upon companies involved in the clinical development, manufacturing, marketing, and distribution of drugs
Major players operating in the global eosinophilic esophagitis market include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH.
Eosinophilic esophagitis is a chronic condition which is treated with the help of steroids and acid suppressants such as proton pump inhibitors. Steroids help control the inflammation. Topical steroids are administered as a inhaler or as a liquid. Oral steroids may be prescribed to treat people who have serious swallowing problems or weight loss. Proton pump inhibitors help with reflux symptoms and decrease inflammation.
Growing awareness regarding eosinophilic esophagitis leads to an increase in demand for treatment products. Thus, key market players are engaged in developing newer treatments and addressing the demand for EoE treatment products. For instance, Sanofi S.A. a global biopharmaceutical company engaged in conducting a phase 3 clinical trial for Dupixent (dupilumab) and is estimated to complete by 2023. Additionally, upcoming innovative products to improve the management of EoE are anticipated to drive the global market growth. For instance, in December 2021, Takeda Pharmaceutical Company Limited a Japanese multinational pharmaceutical company received a Complete Response Letter (CRL) for TAK-721 (budesonide oral suspension) from the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis. In June 2021, the U.S. FDA granted Orphan Drug Designation (ODD) for Etrasimod. Etrasimod had been investigated by Arena Pharmaceuticals, Inc. an American biopharmaceutical company. Moreover, an increase in the prevalence of eosinophilic esophagitis is likely boost the market growth. For instance, according to a study published in the Saudi Medical Journal in July 2018, eosinophilic esophagitis is an emerging disease and has an increasing incidence in children in Saudi Arabia.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients